Institution
University of Paris
Education•Paris, France•
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Medicine. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.
Topics: Population, Medicine, Context (language use), Transplantation, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy.
Abstract: BACKGROUND Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory pressure support on top of expiratory positive airway pressure. We investigated the effects of adaptive servo-ventilation in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea. METHODS We randomly assigned 1325 patients with a left ventricular ejection fraction of 45% or less, an apnea–hypopnea index (AHI) of 15 or more events (occurrences of apnea or hypopnea) per hour, and a predominance of central events to receive guideline-based medical treatment with adaptive servo-ventilation or guidelinebased medical treatment alone (control). The primary end point in the time-toevent analysis was the first event of death from any cause, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock), or unplanned hospitalization for worsening heart failure. RESULTS In the adaptive servo-ventilation group, the mean AHI at 12 months was 6.6 events per hour. The incidence of the primary end point did not differ significantly between the adaptive servo-ventilation group and the control group (54.1% and 50.8%, respectively; hazard ratio, 1.13; 95% confidence interval [CI], 0.97 to 1.31; P = 0.10). All-cause mortality and cardiovascular mortality were significantly higher in the adaptive servo-ventilation group than in the control group (hazard ratio for death from any cause, 1.28; 95% CI, 1.06 to 1.55; P = 0.01; and hazard ratio for cardiovascular death, 1.34; 95% CI, 1.09 to 1.65; P = 0.006). CONCLUSIONS Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy. (Funded by ResMed and others; SERVE-HF ClinicalTrials.gov number, NCT00733343.) abstr act
817 citations
••
University of Cambridge1, University of Kiel2, University of East Anglia3, University of Copenhagen4, University of Manchester5, Karolinska Institutet6, Maastricht University7, Wellcome Trust Sanger Institute8, Trinity College, Dublin9, University of Paris10, University of Birmingham11, Charles University in Prague12, University College London13, University of Parma14, University of Jena15, Lund University16, University of Glasgow17, Imperial College London18, GlaxoSmithKline19, Linköping University20, Ruhr University Bochum21, University of Erlangen-Nuremberg22, Medical University of Vienna23
TL;DR: This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyang iitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature ofproteinase 3 ANCA -associated vasulitis.
Abstract: BACKGROUND Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis. Its cause is unknown, and there is debate about whether it is a single disease entity and what role ANCA plays in its pathogenesis. We investigated its genetic basis. METHODS A genomewide association study was performed in a discovery cohort of 1233 U. K. patients with ANCA-associated vasculitis and 5884 controls and was replicated in 1454 Northern European case patients and 1666 controls. Quality control, population stratification, and statistical analyses were performed according to standard criteria. RESULTS We found both major-histocompatibility-complex (MHC) and non-MHC associations with ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyangiitis were genetically distinct. The strongest genetic associations were with the antigenic specificity of ANCA, not with the clinical syndrome. Anti-proteinase 3 ANCA was associated with HLA-DP and the genes encoding alpha(1)-antitrypsin (SERPINA1) and proteinase 3 (PRTN3) (P = 6.2x10(-89), P = 5.6x10(-12), and P = 2.6x10(-7), respectively). Anti-myeloperoxidase ANCA was associated with HLA-DQ (P = 2.1x10(-8)). CONCLUSIONS This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature of proteinase 3 ANCA-associated vasculitis. These data provide preliminary support for the concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndromes. (Funded by the British Heart Foundation and others.)
816 citations
••
[...]
TL;DR: Genotype and serum viral load are useful predictors of response to treatment and the combination of pegylated interferon and ribavirin can eradicate the virus in more than 50% of patients.
815 citations
••
TL;DR: It is found that this phase transition, in two space dimensions, is always discontinuous, including for the minimal model of Vicsek et al. for which a nontrivial critical point was previously advocated.
Abstract: We study the onset of collective motion, with and without cohesion, of groups of noisy self-propelled particles interacting locally. We find that this phase transition, in two space dimensions, is always discontinuous, including for the minimal model of Vicsek et al. [Phys. Rev. Lett. 75,1226 (1995)] for which a nontrivial critical point was previously advocated. We also show that cohesion is always lost near onset, as a result of the interplay of density, velocity, and shape fluctuations.
815 citations
••
TL;DR: In this article, the safety and efficacy of the combination of peginterferon alfa-2b and ribavirin was evaluated in HCV-infected patients.
Abstract: ContextTreatment of chronic hepatitis C virus (HCV) infection in human immunodeficiency
virus (HIV)–infected patients is a growing concern. Most data on the
virologic efficacy and safety of the combination of peginterferon alfa-2b
and ribavirin in coinfected patients come from uncontrolled studies.ObjectiveTo study the safety and efficacy of peginterferon alfa-2b plus ribavirin
vs standard interferon alfa-2b plus ribavirin in HIV-HCV coinfected patients.Design and SettingsA multicenter, randomized, parallel-group, open-label trial. Patients
were enrolled from February 2000 to February 2002 and followed up for 72 weeks.PatientsFour hundred twelve HIV-HCV coinfected patients with detectable serum
HCV-RNA, abnormal liver histology, a CD4 cell count of at least 200 × 106/L, and stable plasma HIV-RNA.InterventionTreatment with ribavirin 400 mg twice a day, orally, plus either peginterferon
alfa-2b (1.5 μg/kg subcutaneous injection once a week) or standard interferon
alfa-2b (3 million units of subcutaneous injection 3 times a week) for 48
weeks.Main Outcome MeasuresSustained virologic response, defined by undetectable serum HCV-RNA
at week 72.ResultsMore patients had sustained virologic responses in the peginterferon
group than in the standard interferon group (27% vs 20%, P = .047). This difference between the treatments was found
in patients with HCV genotype 1 or 4 infection (17% for peginterferon vs 6%
for standard interferon, P = .006) but
was not found in patients with HCV genotype 2, 3, or 5 (44% for peginterferon
vs 43% for standard interferon, P = .88).
Together, a decline in HCV-RNA of less than 2 log10 from baseline
and detectable serum HCV-RNA at week 12 predicted 99% of treatment failures.
Histologic activity diminished and fibrosis stabilized in virologic responders.
The 2 regimens showed similar tolerability although dose modifications for
clinical and biological events were more frequent with peginterferon. Eleven
cases of pancreatitis or symptomatic hyperlactatemia were observed, all in
patients receiving didanosine-containing antiretroviral regimens.ConclusionIn combination with ribavirin, treatment with peginterferon alfa-2b
is more effective than standard interferon alfa-2b for HCV infection in HIV-infected
patients.
814 citations
Authors
Showing all 102613 results
Name | H-index | Papers | Citations |
---|---|---|---|
Guido Kroemer | 236 | 1404 | 246571 |
David H. Weinberg | 183 | 700 | 171424 |
Paul M. Thompson | 183 | 2271 | 146736 |
Chris Sander | 178 | 713 | 233287 |
Sophie Henrot-Versille | 171 | 957 | 157040 |
Richard H. Friend | 169 | 1182 | 140032 |
George P. Chrousos | 169 | 1612 | 120752 |
Mika Kivimäki | 166 | 1515 | 141468 |
Martin Karplus | 163 | 831 | 138492 |
William J. Sandborn | 162 | 1317 | 108564 |
Darien Wood | 160 | 2174 | 136596 |
Monique M.B. Breteler | 159 | 546 | 93762 |
Paul Emery | 158 | 1314 | 121293 |
Wolfgang Wagner | 156 | 2342 | 123391 |
Joao Seixas | 153 | 1538 | 115070 |